Neuralgia
📧 Sign up to get email alerts when something new happens for Neuralgia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-25EMA Authorised: Lyrica (pregabalin) — Upjohn EESV
The European Medicines Agency authorised pregabalin (brand Lyrica) for epilepsy, anxiety disorders, and neuralgia, with Upjohn EESV as the m…
-
EMA approval · 2026-03-23EMA Authorised: Qutenza (capsaicin) — Grunenthal GmbH
The EMA authorised Qutenza (capsaicin) from Grunenthal GmbH for neuralgia in the European Union.
-
EMA approval · 2025-12-02EMA Authorised: Pregabalin Sandoz (pregabalin) — Sandoz GmbH
The EMA authorised the Sandoz generic pregabalin product for anxiety disorders, neuralgia, and epilepsy.
-
EMA approval · 2025-10-15EMA Authorised: Duloxetine Viatris (previously Duloxetine Mylan) (duloxetine) — Viatris Limited
The European Medicines Agency authorised a duloxetine product marketed as Duloxetine Viatris by Viatris Limited for several indications incl…
-
EMA approval · 2024-07-09EMA Authorised: Duloxetine Lilly (duloxetine) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised duloxetine (Lilly) by Eli Lilly Nederland B.V. for neuralgia, diabetic neuropathies, and major depr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.